12 Aug 2014
Diabetic Retinopathy/Diabetic Macular Edema Compound
Established company with strong IP rights to early stage compound for the treatment of Diabetic Retinopathy/Diabetic Macular Edema wishes to discuss divestiture. Compound is supported by limited clinical data showing improved visual acuity and safety. This is the first topically administered drug to be effective and safe for the treatment of this disease.
The discovery of this compound originated in the finding that elimination of sympathetic neurotransmission to the rat retina reproduces the biochemical and histological features of non-proliferative diabetic retinopathy. This response was reproduced when normal rats were treated systemically with the generic b-adrenergic receptor antagonist, propranolol. This observation led the investigators to conclude that the retinal changes (similar to diabetes) in the rat are due to loss of b-adrenergic receptor signaling. This maintenance of visual function was associated with a decreased level of inflammatory cytokines and increased insulin receptor signaling.
The market for the treatment of diabetic retinopathy is large and represents an unmet medical need. By 2015, an estimated 1.2 million patients in the U.S. alone will have vision threatening Diabetic Retinopathy. Currently, no topical compound exist for the treatment of this disease.
The inventors and owner met with the FDA and received positive feedback regarding their IND application. This drug is Phase II ready and the mechanism of action is supported by solid animal data.
A complete dossier is available upon request. Please contact Commercial Healthcare Partners for more information. Contact information below:
Jim Usry, Principal
Return to Press Releases